Toll-Like Receptor 7 Ligand II – 500 µg

Brand:
Cayman
CAS:
226907-52-4
Storage:
-20
UN-No:
Non-Hazardous - /

A potential treatment for hepatitis C virus (HCV) is to induce immune cell-derived interferon (IFN) production using synthetic agonists of toll-like receptor 7 (TLR7). TLR7 ligand II is an orally bioavailable 8-hydroxyadenine analog that induces IFN production by binding to TLR7 on immune cells.{28465,28466} It induces IFNα in human peripheral blood mononuclear cells with an EC50 value of 0.14 µM.{28466} At 10 µM, TLR7 ligand II was shown to reduce HCV levels by 60% in 24 hours in the human hepatocyte cell line Huh7, which carries a HCV replicon.{28467} It induces IFN in mice with a minimal effective dose of approximately 0.03 mg/kg, making it approximately 100-fold more potent than imiquimod (Item No. 14956).{28465}  

 

Out of stock

SKU: - Category:

Description

An orally bioavailable 8-hydroxyadenine analog that induces IFN production by binding to TLR7 on immune cells; induces IFNα in human peripheral blood mononuclear cells (EC50 = 0.14 µM); reduces HCV in Huh7 cells that carry a HCV replicon


Formal name: 6-amino-7,9-dihydro-2-(2-methoxyethoxy)-9-(phenylmethyl)-8H-purin-8-one

Synonyms:  1V136|CL 087|SM-360320|TLR7 Ligand II

Molecular weight: 315.3

CAS: 226907-52-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Immunology & Inflammation|Innate Immunity|Pattern Recognition||Research Area|Infectious Disease|Viral Diseases|Hepatitis